{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:20:08Z","timestamp":1792516808151,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (200-600 mg) and rituximab over 6 months and then received venetoclax monotherapy. Patients achieving complete response (CR), CR with incomplete marrow recovery (CRi), or undetectable minimal residual disease (uMRD) assessed by flow cytometry (&amp;lt;10\u22124 cutoff) were allowed, but not required, to discontinue therapy, while remaining in the study and could be retreated with VenR upon progression. Median follow-up for all patients (N = 49) was 5.3 years. Five-year rates (95% CI) for overall survival, progression-free survival, and duration of response were 86% (72-94), 56% (40-70), and 58% (40-73), respectively. Of the 33 deep responders (CR\/CRi or uMRD), 14 remained on venetoclax monotherapy (continuous therapy), and 19 stopped venetoclax therapy (limited-duration therapy) after a median of 1.4 years. Five-year estimates of ongoing response were similar between continuous (71%; 95% CI, 39-88) or limited-duration therapy (79% [49-93]). Six of 19 patients in the latter group had subsequent disease progression, all &amp;gt;2 years off venetoclax (range, 2.1-6.4). Four patients were retreated with VenR, with partial responses observed in the 3 evaluable to date. VenR induced deep responses that were highly durable with either continuous or limited-duration therapy. Retreatment with VenR induced responses in patients with CLL progression after discontinuing therapy. Continuous exposure to venetoclax in deep responders does not appear to provide incremental benefit.<\/jats:p>","DOI":"10.1182\/blood.2020009578","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T18:01:54Z","timestamp":1622829714000},"page":"836-846","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy"],"prefix":"10.1182","volume":"138","author":[{"given":"Shuo","family":"Ma","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;"},{"name":"University of Melbourne, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"University of California San Diego, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Choi","sequence":"additional","affiliation":[{"name":"University of California San Diego, San Diego, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;"},{"name":"University of Melbourne, Parkville, VIC, Australia;"},{"name":"Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Humphrey","sequence":"additional","affiliation":[{"name":"Roche, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al Masud","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pesko","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Nandam","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"},{"name":"Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Chyla","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Arzt","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Jacobson","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Young","family":"Kim","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;"},{"name":"University of Melbourne, Parkville, VIC, Australia;"},{"name":"Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"2","key":"2021090915300829600_B1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood."},{"issue":"3","key":"2021090915300829600_B2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood."},{"issue":"11","key":"2021090915300829600_B3","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood."},{"key":"2021090915300829600_B4","author":"National Comprehensive Cancer Network","year":"2020"},{"issue":"19","key":"2021090915300829600_B5","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood."},{"issue":"25","key":"2021090915300829600_B6","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2021090915300829600_B7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med."},{"issue":"25","key":"2021090915300829600_B8","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021090915300829600_B9","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med."},{"issue":"1","key":"2021090915300829600_B10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med."},{"issue":"12","key":"2021090915300829600_B11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol."},{"issue":"2","key":"2021090915300829600_B12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med."},{"issue":"12","key":"2021090915300829600_B13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med."},{"issue":"23","key":"2021090915300829600_B14","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med."},{"issue":"1","key":"2021090915300829600_B15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cpt.553","article-title":"Targeting BCL2 with BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies","volume":"101","author":"Roberts","year":"2017","journal-title":"Clin Pharmacol Ther."},{"issue":"4","key":"2021090915300829600_B16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"2021090915300829600_B17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"issue":"19","key":"2021090915300829600_B18","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial [published correction appears in J Clin Oncol. 2019;37(25):2299]","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021090915300829600_B19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"2021090915300829600_B20","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood."},{"issue":"28","key":"2021090915300829600_B21","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021090915300829600_B22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"issue":"10","key":"2021090915300829600_B23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood."},{"key":"2021090915300829600_B24","author":"VENCLEXTA [prescribing information]. North Chicago, IL: AbbVie Inc.; South San Francisco, CA: Genentech USA, Inc","year":"2019"},{"issue":"4","key":"2021090915300829600_B25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol."},{"key":"2021090915300829600_B26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123930","article-title":"Four-year analysis of MURANO study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) [abstract]","volume":"134","author":"Seymour","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2021090915300829600_B27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/bloodadvances.2019000864","article-title":"Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months","volume":"4","author":"Lew","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2021090915300829600_B28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/10\/836\/1821463\/bloodbld2020009578.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/10\/836\/1821463\/bloodbld2020009578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T11:32:26Z","timestamp":1631187146000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/10\/836\/476062\/Efficacy-of-venetoclax-plus-rituximab-for-relapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,3]]},"published-print":{"date-parts":[[2021,9,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009578","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]}}}